Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs TransMedics Group Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.84, while TransMedics Group Inc trades at $71.47 (market cap $2.57B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| PDBC | TMDX | |
|---|---|---|
52-Week High | $18.91 | $150.42 |
52-Week Low | $12.90 | $61.99 |
Market Cap | — | $2.57B |
Sector | — | Technology |
Enterprise Value | — | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.65, up 2.32% today, reflecting strong commodity momentum. The technical outlook is bullish with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent news highlights institutional accumulation, such as Geneos Wealth Management increasing its stake by 150.6% in Q1 2026 (Defense World, 2026-07-19). The fund has delivered significant returns, up 37% since March 2024, driven by energy price surges and supply disruptions.
The outlook for PDBC remains positive as a diversified commodities play and inflation hedge, but risks include commodity price volatility and the fund's structural costs. Momentum may weaken if oil prices retreat, as noted in a recent downgrade to hold (Seeking Alpha, 2026-06-11). Investors should weigh the fund's tax advantages against roll costs and cyclical commodity exposure.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
